Involvement of MicroRNA-198 Overexpression in the Poor Prognosis of Esophageal Cancer

Qi, Bo; Yao, Wenjian; Zhao, Baosheng; Qin, Xiuguang; Wang, Yi; Wang, Wenju; Wang, Tianyun; Liu, Shangguo; Li, Hanchen

doi:10.7314/apjcp.2013.14.9.5073

Cited by 21 publications

(21 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to now, lower expression of miR-198 has been reported in lung adenocarcinoma,4 pancreatic cancer,20 and colorectal cancer 10. However, higher expressed miR-198 has been confirmed in other malignancies such as retinoblastoma,7 squamous cell carcinoma of tongue,6 esophageal cancer,5 pancreatic adenocarcinoma or ampullary adenocarcinoma,8 prostate cancer,11 and multiple myeloma 9. Overexpression of miR-198 has also been found in noncancerous diseases such as severe preeclampsia,21 lupus nephritis,22 and human anencephaly 23.…”

Section: Discussionmentioning

confidence: 99%

“…From nearly all biological processes, miRNA can exert the function as posttranscriptional regulation 3. Aberrant expression of microRNA-198 (miR-198) has been found to be correlated to the carcinogenesis and disease progression of several classes of cancers, including lung adenocarcinoma,4 esophageal cancer,5 squamous cell carcinoma of tongue,6 retinoblastoma,7 pancreatic adenocarcinoma,8 multiple myeloma,9 colorectal cancer,10 and prostate cancer 11. However, there were only three research papers studying the expression of miR-198 in HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study

Huang¹,

Wang²,

Yang

et al. 2016

OTT

View full text Add to dashboard Cite

PurposeTo investigate the clinicopathological value and potential roles of microRNA-198 (miR-198) in hepatocellular carcinoma (HCC).MethodsNinety-five formalin-fixed paraffin-embedded HCC and the para-cancerous liver tissues were gathered. Real-time reverse transcription quantitative polymerase chain reaction was applied to determine the miR-198 expression. The association between the miR-198 expression and clinicopathological features was examined. Meanwhile, potential target messenger RNAs of miR-198 in HCC were obtained from 14 miRNA prediction databases and natural language processing method, in which we pooled the genes related to the tumorigenesis and progression of HCC and classified them by their frequency. The selected target genes were finally analyzed in the Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes pathway.ResultsmiR-198 expression was significantly lower in HCC than that in adjacent noncancerous liver tissues (1.30±0.72 vs 2.01±0.58, P<0.001). Low miR-198 expression was also correlated to hepatitis C virus infection (r=−0.48, P<0.001), tumor capsular infiltration (r=−0.43, P<0.001), metastasis (r=−0.26, P<0.010), number of tumor nodes (r=−0.25, P=0.013), vaso-invasion (r=−0.24, P=0.017), and clinical tumor node metastasis stage (r=−0.23, P=0.024). Altogether, 1,048 genes were achieved by the concurrent prediction from at least four databases and natural language processing indicated 1,800 genes for HCC. Further, 127 overlapping targets were further proceeded with for pathway analysis. The most enriched Gene Ontology terms in the potential target messenger RNAs of miR-198 were cell motion, cell migration, cell motility, and regulation of cell proliferation in biological process; organelle lumen, membrane-enclosed lumen, and nuclear lumen in cellular component; and enzyme binding, protein domain-specific binding, and protein kinase activity in molecular function. Kyoto Encyclopedia of Genes and Genomes analysis showed that these target genes were obviously involved in focal adhesion and pathways in cancer.ConclusionLower expression of miR-198 was related to several clinicopathological parameters in HCC patients. miR-198 might play a regulatory role through its target genes in the development of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study

Huang¹,

Wang²,

Yang

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…In human cancers, miR-198 was reported to be downregulated in colorectal (4), lung (5), pancreatic (6) and hepatocellular carcinoma (8,9), and generally acts as a tumor suppressor by inhibiting cancer cell growth and migration. In contrast, high expression of miR-198 was noted to be associated with a shorter disease-free survival and overall survival time in pancreatic ductal adenocarcinomas (7), with poor prognosis in esophageal cancer (11) and in high-grade prostate tumors (10). These data suggest that the roles of miR-198 may vary in different types of cancer.…”

Section: Cdcp1 Expression -------------------------------------------mentioning

confidence: 99%

“…miRNAs have been implicated in a variety of biological processes, including embryonic development, cell differentiation and diseases including human cancer (3). miR-198 has been reported to be deregulated in several human cancers, including colorectal (4), lung (5), pancreatic (6,7), hepato cellular (8,9), prostate (10) and esophageal cancer (11). However, the involvement and effects of miR-198 on breast cancer progression and the underlying mechanism remain unknown.…”

Section: Introductionmentioning

confidence: 99%

miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1

Tang

Jiang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The molecular mechanisms underlying the dysregulation of microRNAs (miRs) have been previously documented in breast cancer. miR-198 has been reported to be deregulated in several human cancers. However, the detailed effects of miR-198 on breast cancer progression remain unclear. Using quantitative polymerase chain reaction analysis, we demonstrated in the present study that miR-198 was downregulated in breast cancer tissues and cell lines, and that downregulation of miR-198 was significantly correlated with lymph node metastasis. Functional studies revealed that miR-198 inhibited cell proliferation and migration and promoted cell adhesion in aggressive breast cancer cells in vitro. In addition, we observed that CUB domain-containing protein 1 (CDCP1) was a direct target of miR-198, and that knockdown of CDCP1 inhibited cell proliferation and migration, and promoted cell adhesion, which was similar to the effects of overexpression of miR-198. Taken together, we provide evidence to characterize the role of miR-198/CDCP1 interaction in breast cancer, which may be useful in breast cancer therapy.

show abstract

“…Until now, EC has low survival rate because of its aggressive nature, distant metastasis, and largely unknown molecular mechanism of progression (He et al, 2012;Wang et al, 2013;). To determine a specific biomarker at the gene level and establish effective prevention, obtaining an early diagnosis method has become one of the research focuses in the field of tumor and EC prevention (Qi et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Stathmin is a Marker of Progression and Poor Prognosis in Esophageal Carcinoma

Wang

Xing²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Stathmin, also called oncoprotein 18, is a founding member of the family of microtubule-destabilizing proteins that play a critical role in the regulation of mitosis. At the same time stathmin has been recognized as one of responsible factors in cancer cells. The aim of this study was to assess stathmin status, its correlations with clinicopathological parameters and its role as a progosnostic marker in EC patients. The protein and mRNA levels of stathmin were examined byimmunohistochemistry (IHC) and in situ hybridization in 100EC tissues and adjacent noncancerous tissues. mRNA and protein expression of stathmin in three EC cell lines(EC9706, ECa109, EC1 commonly used in research) were also analyzed using immunocytochemistry, western blot and in situ hybridization. The prognostic value of Stathmin expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. We showed that stathmin expression was significantly higher in EC tissues than in adjacent noncancerous tissues. High stathmin immunostaining score in the EC was positively correlated with tumor differentiation, Tumor invasion, Lymph node metastases, and TNM stage. In addition, we demonstrated that three EC cell lines examined, were constitutively expressing a high level of stathmin. Of those, EC-1 showed the strongest mRNA and protein expression for the stathmin analyzed. Kaplan-Meier analysis showed that significantly longer 5-year survival rate was seen in EC patients with high Stathmin expression, compared to those with low expression of Stathmin expression. Furthermore, multivariate Cox proportional hazard analyses revealed that Stathmin was an independent factors affecting the overall survival probability. In conclusion, our data provide a basis for the concept that stathmin might be associated with EC development and progression.. High levels of Stathmin expression in the tumor tissues may be a good prognostic marker for patients with EC.

show abstract

Involvement of MicroRNA-198 Overexpression in the Poor Prognosis of Esophageal Cancer

Cited by 21 publications

References 20 publications

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study

miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1

Stathmin is a Marker of Progression and Poor Prognosis in Esophageal Carcinoma

Contact Info

Product

Resources

About